McKesson stock hits all-time high, reaching $737.0 USD

McKesson Corporation (MCK) recently reached a new all-time stock high of $737.0, marking a 25.31% annual gain and supported by 16.22% revenue growth, reflecting robust market confidence. Despite Q3 2025 revenue of $90.82 billion slightly missing forecasts, adjusted EPS of $10.12 surpassed expectations, while the company maintains a "GREAT" financial health score and actively buys back shares. Strategic initiatives, including the $2.49 billion acquisition of Core Ventures for oncology care and the planned divestiture of its MedSurg segment, underscore McKesson's focus on its core U.S. Pharmaceutical business and long-term EPS growth outlook of 12-14%, prompting analysts like Morgan Stanley and Jefferies to raise price targets.

Analysis

McKesson Corporation (MCK) has demonstrated significant market strength, with its stock reaching a new all-time high of $737.0, culminating a 25.31% increase over the past year. This performance is underpinned by robust top-line growth of 16.22% and a "GREAT" financial health score, further supported by management's confidence as evidenced by active share buybacks. The most recent quarterly results present a mixed picture: Q3 2025 adjusted EPS of $10.12 surpassed the $9.81 forecast, indicating strong profitability, yet revenue of $90.82 billion fell short of the $93.48 billion expectation. Strategically, McKesson is refining its portfolio by acquiring a 70% stake in Core Ventures for approximately $2.49 billion to bolster its presence in community oncology, while simultaneously planning to divest its MedSurg segment. This aligns with its stated focus on the core U.S. Pharmaceutical segment and a long-term EPS growth outlook of 12-14%. Analyst sentiment is largely positive, with Morgan Stanley and Jefferies raising price targets to $770 and $800 respectively, while Wells Fargo maintains a more neutral "Equal Weight" rating with a $766 target.

Key Decisions for Investors

• Despite the stock reaching an all-time high, the strong fundamentals, ongoing share buybacks, and positive analyst revisions suggest continued momentum, warranting a constructive view on existing positions.
• Investors should closely monitor upcoming quarterly revenue reports to ascertain whether the recent miss was a one-off event or the beginning of a decelerating growth trend, which represents the key risk to the current bull case.
• The strategic initiatives, namely the integration of the Core Ventures acquisition and the execution of the MedSurg divestiture, should be tracked as key catalysts for realizing the company's long-term 12-14% EPS growth target.
• Considering the stock is described as fairly valued at its peak, potential new investors might look for market pullbacks to establish a position, while noting that several analyst targets still imply moderate upside from current levels.